Roche announced that its Elecsys IGRA TB test has received the CE Mark, introducing a new blood testing solution for identifying tuberculosis infection (TBI, also known as latent… read more.
The Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a marketing authorisation in the EU for the medicinal product Icotyde (icotrokinra), intended for… read more.
Earlier toilet training and new recycling technologies are among expert-backed solutions to reduce the environmental impact of disposable nappies and other hygiene products, described in a new study… read more.
A new oral antiviral drug candidate administered either before or after direct contact or airborne exposure to canine distemper virus, which causes measles-like disease in ferrets, blocks transmission… read more.
Boehringer Ingelheim announced that the European Commission (EC) has granted marketing authorization for Jascayd (nerandomilast) for the treatment of adults with idiopathic pulmonary fibrosis (IPF) and adults with… read more.
Eisai Co., Ltd. and Biogen Inc. announced that the FDA has approved a supplemental Biologics License Application (sBLA) for a once-weekly lecanemab-irmb subcutaneous injection (brand name: Leqembi IQLIK)… read more.
Gilead Sciences announced that the CHMP of the European Medicines Agency (EMA) has adopted a positive opinion, recommending the marketing authorization of Trodelvy (sacituzumab govitecan-hziy) in combination with… read more.
Metabolic dysfunction‑associated fatty liver disease (MAFLD) is a leading chronic liver disease in China, yet primary care capacity remains limited. To address this, the first national Guidelines for Diagnosis… read more.
Many countries are using too many powerful and inappropriate antibiotics, fuelling antibiotic resistance concerns, while millions lack access to the specific drugs they need. That is according to… read more.
Roche announced that the CHMP has recommended the approval of Susvimo (ranibizumab injection) 100 mg/mL for the treatment of neovascular age-related macular degeneration (nAMD). Susvimo is intended for… read more.
Pfizer announced that the FDA accepted for Priority Review a supplemental New Drug Application (sNDA) for Talzenna (talazoparib), an oral poly ADP-ribose polymerase (PARP) inhibitor, in combination with… read more.
Organon will present results from a post hoc analysis of pooled data from the Phase 3 pivotal trials, ADORING 1 and ADORING 2, evaluating the efficacy and safety… read more.
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
